BTG plc (BTG) Price Target Increased to GBX 830 by Analysts at JPMorgan Chase & Co.
BTG plc (LON:BTG) had its price objective raised by JPMorgan Chase & Co. from GBX 790 ($10.31) to GBX 830 ($10.83) in a research report report published on Friday morning. The brokerage currently has a neutral rating on the stock.
Other analysts also recently issued reports about the company. Deutsche Bank AG raised their target price on BTG plc from GBX 740 ($9.66) to GBX 840 ($10.96) and gave the stock a buy rating in a research report on Tuesday, July 12th. Stifel Nicolaus reaffirmed a hold rating and issued a GBX 640 ($8.35) price target on shares of BTG plc in a report on Thursday. Jefferies Group reaffirmed a buy rating and issued a GBX 860 ($11.23) price target on shares of BTG plc in a report on Friday, July 15th. Finally, Numis Securities Ltd reaffirmed a hold rating and issued a GBX 737 ($9.62) price target on shares of BTG plc in a report on Thursday. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. BTG plc currently has a consensus rating of Buy and an average price target of GBX 799.57 ($10.44).
Shares of BTG plc (LON:BTG) traded down 0.43% during trading on Friday, reaching GBX 698.50. The company’s stock had a trading volume of 304,086 shares. The stock’s 50-day moving average is GBX 629.82 and its 200-day moving average is GBX 641.22. The stock’s market cap is GBX 2.67 billion. BTG plc has a 12-month low of GBX 504.00 and a 12-month high of GBX 739.50.
In other BTG plc news, insider Soderstrom,Rolf sold 74,327 shares of the firm’s stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of GBX 676 ($8.82), for a total transaction of £502,450.52 ($655,855.01).
About BTG plc
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.